Holen Sie sich die Stockscreener-App
107.55
0.78%
-0.76
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Halozyme Therapeutics (NASDAQ:HALO) Screens Well on High Growth Momentum and Breakout Setup - ChartMill
Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now? - Zacks Investment Research
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Biotech Powerhouse with a Revenue Growth of 47.70% - DirectorsTalk Interviews
Biotech Stocks At 52-Week HighsATTO, HALO, IKT, TVTX, ATRC - RTTNews
Halozyme Therapeutics | SCHEDULE 13G: Others - Moomoo
Halozyme Therapeutics stock hits all-time high at 109.69 USD By Investing.com - Investing.com Nigeria
Halozyme (NASDAQ: HALO) awards board member new RSUs and options vesting at 2027 meeting - Stock Titan
Halozyme Therapeutics stock hits all-time high at 109.69 USD - Investing.com
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $115 - Moomoo
Halozyme Investor Conferences Put ENHANZE and Expanded Drug Delivery Portfolio in Focus - Yahoo Finance
Halozyme to Participate at Upcoming Investor Conferences - marketscreener.com
Three Halozyme executive talks will be webcast in September - Stock Titan
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Halozyme: The Market May Be Underpricing The Second Growth Wave (NASDAQ:HALO) - Seeking Alpha
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Robust Growth Trajectory in the Biotech Sector - DirectorsTalk Interviews
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice - Eastern Progress
Halozyme Therapeutics (HALO) Stock Trades At A Premium To Fair Value - Yahoo Finance
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Eastern Progress
Halozyme Therapeutics stock hits all-time high at 109.59 USD By Investing.com - Investing.com Nigeria
Halozyme Therapeutics stock hits all-time high at 109.59 USD - Investing.com
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Strong Revenue Growth and Robust Pipeline Drive Investor Interest - DirectorsTalk Interviews
Halozyme (HALO) Stock Could Be Fully Priced On The Board Appointment - Sahm
New Halozyme (NASDAQ: HALO) director logs zero stock in first ownership filing - Stock Titan
HALO Stock Rises 36% in a Month: Here's What You Should Know - TradingView
Great Lakes Advisors LLC Purchases Shares of 36,039 Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (HALO) Adds A New Director, Is It 21% Overvalued? - Sahm
Aurora Investment Counsel Takes Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme CEO Helen Torley sells $6.28m in company shares By Investing.com - Investing.com Australia
Halozyme CEO Helen Torley sells $6.28m in company shares - Investing.com
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock - MarketBeat
Halozyme (NASDAQ: HALO) CEO sells tens of thousands of shares - Stock Titan
Halozyme (HALO) Levels: Moves 2.60% Up to $107.62 in the Latest Reading; Range View: Price Remains Between $102.24 Support and $113.00 Resistance for the Current SessionInsider Buying Alerts - Vinanet
Halozyme Appoints Dannielle Appelhans to Board of Directors - The Globe and Mail
Foster & Motley Inc. Invests $2 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Diversify Advisory Services LLC Invests $2.77 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics(HALO.US) Officer Sells US$6.28 Million in Common Stock - Moomoo
Halozyme Therapeutics Appoints Dannielle Appelhans to Board of Directors - Kalkine Media
Halozyme Therapeutics (NASDAQ:HALO): What Is Driving the Rally? - Kalkine Media
Halozyme adds Dannielle Appelhans to board of directors - Investing.com
Halozyme adds Dannielle Appelhans to board of directors By Investing.com - Investing.com Australia
Halozyme Therapeutics stock hits all-time high of 104.86 USD By Investing.com - Investing.com Australia
Halozyme Appoints Dannielle Appelhans to its Board of Directors - PR Newswire
Halozyme Therapeutics (NASDAQ:HALO) Reaches New 52-Week HighWhat's Next? - MarketBeat
Halozyme Therapeutics stock hits all-time high of 104.86 USD - Investing.com
H.C. Wainwright reiterates Halozyme stock rating on partner data By Investing.com - Investing.com Canada
HALO Q2 2026 Earnings: EPS Surges 21.75% Above Estimates, Shares Climb 4.4%New Analyst Coverage - Vinanet
Halozyme (NASDAQ: HALO) insider lines up new stock sale after recent disposals - Stock Titan
Horizon Investment Services LLC Buys Shares of 28,793 Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Biotech Powerhouse with Robust Revenue Growth - DirectorsTalk Interviews
Chase Investment Counsel Corp Buys New Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call - Yahoo Finance
Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics? - Yahoo Finance
Halozyme (HALO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
Is Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo Finance
Wedge Capital Management L L P NC Invests $31.61 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Handelsbanken Fonder AB Grows Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
0.61%
3.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):